注射毒品人群丙型肝炎病毒感染的综合治疗:多中心随机对照试验(INTRO-HCV)
INTRO-HCV 是一项多中心随机对照试验,纳入 298 名注射毒品者,比较综合治疗(在阿片受体激动剂治疗诊所或社区护理中心由多学科团队提供检测、纤维化评估、咨询、治疗和随访)与标准治疗(医院门诊)的疗效。综合治疗组启动治疗时间显著更短(HR 2.2,95%CI 1.7–2.9),持续病毒学应答(SVR)在全体人群中更高(OR 2.8,95%CI 1.6–4.8),在已启动治疗者中两组 SVR 率相当。
要点
- 综合治疗显著缩短注射毒品者丙肝治疗启动时间(HR 2.2)。
- 综合治疗组全体人群 SVR 率更高(OR 2.8),已启动治疗者 SVR 率与标准治疗相当。
- 未发现与治疗相关的严重不良事件。
核心结论
- 综合治疗在启动治疗时间上优于标准治疗,且更多患者获得 SVR。
- 在已启动治疗者中,两组 SVR 率相当。
- 扩大综合治疗模式可能是消除丙肝的重要工具。
研究设计与样本
- 多中心、随机对照临床试验(INTRO-HCV),2017–2019 年挪威招募。
- 从阿片受体激动剂治疗诊所和社区护理诊所招募 298 名注射毒品者,1:1 随机分配。
- 综合治疗由多学科团队在阿片受体激动剂治疗诊所或社区护理中心提供。
- 标准治疗在医院门诊提供,两组均使用口服直接抗病毒药物。
- 研究未完全设盲,主要结局为治疗启动时间和 SVR(治疗结束后 12 周 HCV RNA 不可测),意向性分析。
主要发现
- 标准治疗组 150 例中 116 例(77%)启动治疗,108 例(72%)在转诊后 1 年内启动。
- 综合治疗组 148 例中 145 例(98%)启动治疗,141 例(95%)在转诊后 1 年内启动。
- 综合治疗组启动治疗时间的 HR 为 2.2(95%CI 1.7–2.9)。
- 综合治疗组 SVR 确认 123 例(占启动治疗者 85%,占全部 83%);标准治疗组 96 例(占启动治疗者 83%,占全部 64%)。
- SVR 的 OR:已治疗者 1.5(95%CI 0.8–2.9),全体人群 2.8(95%CI 1.6–4.8)。
临床怎么用
- 对注射毒品者,可考虑在阿片受体激动剂治疗诊所或社区护理中心提供综合丙肝治疗以提高治疗启动率。
- 综合治疗模式可能有助于提高全体人群的 SVR 率。
局限性
- 研究未完全设盲。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The standard pathways of testing and treatment for hepatitis C virus (HCV) infection in tertiary healthcare are not easily accessed by people who inject drugs (PWID). The aim of this study was to evaluate the efficacy of integrated treatment of chronic HCV infection among PWID. METHODS AND FINDINGS: INTRO-HCV is a multicenter, randomized controlled clinical trial. Participants recruited from opioid agonist therapy (OAT) and community care clinics in Norway over 2017 to 2019 were randomly 1:1 assigned to the 2 treatment approaches. Integrated treatment was delivered by multidisciplinary teams at opioid agonist treatment clinics or community care centers (CCCs) for people with substance use disorders. This included on-site testing for HCV, liver fibrosis assessment, counseling, treatment, and posttreatment follow-up. Standard treatment was delivered in hospital outpatient clinics. Oral direct-acting antiviral (DAA) medications were administered in both arms. The study was not completely blinded. The primary outcomes were time-to-treatment initiation and sustained virologic response (SVR), defined as undetectable HCV RNA 12 weeks after treatment completion, analyzed with intention to treat, and presented as hazard ratio (HR) and odds ratio (OR) with 95% confidence intervals. Among 298 included participants, 150 were randomized to standard treatment, of which 116/150 (77%) initiated treatment, with 108/150 (72%) initiating within 1 year of referral. Among those 148 randomized to integrated care, 145/148 (98%) initiated treatment, with 141/148 (95%) initiating within 1 year of referral. The HR for the time to initiating treatment in the integrated arm was 2.2 (1.7 to 2.9) compared to standard treatment. SVR was confirmed in 123 (85% of initiated/83% of all) for integrated treatment compared to 96 (83% of initiated/64% of all) for the standard treatment (OR among treated: 1.5 [0.8 to 2.9], among all: 2.8 [1.6 to 4.8]). No severe adverse events were linked to the treatment. CONCLUSIONS: Integrated treatment for HCV in PWID was superior to standard treatment in terms of time-to-treatment initiation, and subsequently, more people achieved SVR. Among those who initiated treatment, the SVR rates were comparable. Scaling up of integrated treatment models could be an important tool for elimination of HCV. TRIAL REGISTRATION: ClinicalTrials.gov.no NCT03155906.
引用
- Fadnes LT, Aas CF, Vold JH, et al. Integrated treatment of hepatitis C virus infection among people who inject drugs: A multicenter randomized controlled trial (INTRO-HCV). PLoS Med. 2021. PMID: 34061883. doi:10.1371/journal.pmed.1003653
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。